PULM Stock Forecast: Pulmatrix, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.28
−10.21% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$4.6M
Ticker Nerd rank
47/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.0M
Net income−$1.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
−10.8%
YTD
−42.8%
1Y
−72.7%
From 52W high
−72.9%
From 52W low
+7.1%
$1.19
$4.70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmatrix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
77
Accruals
75
Issuance
72
Volatility
71
Value
40
Quality
23
Revisions
20
Momentum
11

Growth (77): Sales and profits are climbing, and climbing faster than before.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PULM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PULM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26PULM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Aug 2023HC Wainwright & Co.ReiteratesBuy$10
15 May 2023HC Wainwright & Co.ReiteratesBuy—
7 Feb 2023HC Wainwright & Co.ReiteratesBuy—
30 Mar 2022HC Wainwright & Co.MaintainsBuy—
13 Apr 2021HC Wainwright & Co.MaintainsBuy$10 → $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PULM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PULM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pulmatrix, Inc. returned −72.7% against +6.9% for the S&P 500, dividends included.

PULM vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PULMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PULM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
13.0×

Cheaper than 5% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−143.1%

Higher than 10% of US stocks

Return on assets
−76.0%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulmatrix, Inc. has a market value of $4.6M and an enterprise value of $4.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$4.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$3.9M.

  • Shares outstanding: 3.7M.

  • Pulmatrix, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

PULM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PULMPulmatrix, Inc.$4.6M47
SNTISenti Biosciences Holdings, Inc.$4.6M33
CDIOCardio Diagnostics Holdings, Inc.$4.7M20
AIMAIM ImmunoTech, Inc.$4.5M33
NIKINiki Biosolutions, Inc.$4.9M9
PCSAProcessa Pharmaceuticals, Inc.$4.4M21
ICUSeastar Medical Holding Corp.$5.0M26

Take a look at PULM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulmatrix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PULM

How does Ticker Nerd's model rank PULM?

As at 21 Nov 2026, Pulmatrix, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (77 of 100).

What is the PULM stock forecast for 2030?

No analyst covering Pulmatrix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PULM are extrapolating price history, which says nothing about the business.

How has PULM stock performed over the past year?

Pulmatrix, Inc. returned -72.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmatrix, Inc. do?

Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use.

Company

About Pulmatrix, Inc.

Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use. Pulmatrix’s current product candidates address serious conditions with unmet medical needs, including chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, and acute migraine. Its research and development activity is concentrated on creating inhaled formulations that may improve drug delivery efficiency and patient tolerability. Based in Framingham, Massachusetts, Pulmatrix operates within the biotechnology and pharmaceutical sectors, where it contributes to the development of specialized pulmonary-delivered therapeutics.

CEO Mr. Peter Ludlum CMA, MBA · 2 employees · United States · https://www.pulmatrix.com